Nonalcoholic Steatohepatitis: A 9-Year Follow Up Cohort Study.
Alessandra MangiaAnnarita Valeria PiazzollaMaria Maddalena SquillanteGiovanna CocomazziVanna Maria ValoriMassimiliano CopettiPaola ParenteVito AttinoMaria GuidoPublished in: Journal of clinical medicine (2022)
Our results reinforce the evidence that, in the absence of pharmacologic treatment, NASH progresses in about 40% of patients. Liver biopsy is the only mean to discriminate NAFL from NASH. The prognostic role of portal inflammation needs to be explored in larger series.